GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Mega Genomics Ltd (HKSE:06667) » Definitions » Scaled Net Operating Assets

Mega Genomics (HKSE:06667) Scaled Net Operating Assets : 0.24 (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Mega Genomics Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Mega Genomics's operating assets for the quarter that ended in Jun. 2024 was HK$347.9 Mil. Mega Genomics's operating liabilities for the quarter that ended in Jun. 2024 was HK$137.8 Mil. Mega Genomics's Total Assets for the quarter that ended in Dec. 2023 was HK$871.2 Mil. Therefore, Mega Genomics's scaled net operating assets (SNOA) for the quarter that ended in Jun. 2024 was 0.24.


Mega Genomics Scaled Net Operating Assets Historical Data

The historical data trend for Mega Genomics's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mega Genomics Scaled Net Operating Assets Chart

Mega Genomics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Scaled Net Operating Assets
0.49 0.56 1.06 0.27 0.24

Mega Genomics Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only 0.36 0.29 0.33 0.24 0.24

Competitive Comparison of Mega Genomics's Scaled Net Operating Assets

For the Diagnostics & Research subindustry, Mega Genomics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mega Genomics's Scaled Net Operating Assets Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Mega Genomics's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Mega Genomics's Scaled Net Operating Assets falls into.



Mega Genomics Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Mega Genomics's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2023 )
=(Operating Assets (A: Dec. 2023 )-Operating Liabilities (A: Dec. 2023 ))/Total Assets (A: Dec. 2022 )
=(304.347-112.827)/788.064
=0.24

where

Operating Assets(A: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=871.241 - 566.894
=304.347

Operating Liabilities(A: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=165.943 - 39.413 - 13.703
=112.827

Mega Genomics's Scaled Net Operating Assets (SNOA) for the quarter that ended in Jun. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Jun. 2024 )
=(Operating Assets (Q: Jun. 2024 )-Operating Liabilities (Q: Jun. 2024 ))/Total Assets (Q: Dec. 2023 )
=(347.87-137.804)/871.241
=0.24

where

Operating Assets(Q: Jun. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=895.757 - 547.887
=347.87

Operating Liabilities(Q: Jun. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=182.398 - 40.23 - 4.364
=137.804

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mega Genomics Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Mega Genomics's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Mega Genomics Business Description

Traded in Other Exchanges
N/A
Address
North Garden Road, 401 Health Work, Haidian District, Beijing, CHN
Mega Genomics Ltd is a genetic testing platform company in China with a focus on consumer genetic testing and cancer screening services. The company has launched dozens of testing services, covering a wide range of fields such as nutrition and metabolism, cancer risk assessment, chronic disease susceptibility, cancer screening, and infectious disease diagnosis, to meet consumers growing preventive medical needs. It generates a majority of its revenue from consumer genetic testing services.
Executives
Dongyin Industrial (shenzhen) Co., Ltd. 2106 Person having a security interest in shares
Dongyin (tianjin) Enterprise Management Consulting Co., Ltd. 2106 Person having a security interest in shares
Dongfu Hetong (tianjin) Equity Investment Fund Partnership Enterprise (limited Partnership) 2106 Person having a security interest in shares
Yurong Technology Limited 2101 Beneficial owner
Dongfu (beijing) Investment Management Co., Ltd. 2106 Person having a security interest in shares
Dong Yin Development (holdings) Limited 2106 Person having a security interest in shares
China Orient Asset Management Co., Ltd. 2106 Person having a security interest in shares
Beijing Dongfu Huitong Investment Management Center (limited Partnership) 2106 Person having a security interest in shares
Guo Meiling 2101 Beneficial owner
Yu Rong 2501 Other
Lin Lin 2101 Beneficial owner
Infinite Galaxy Health Limited 2101 Beneficial owner
Bei Jing He He Heng Ye Ke Ji You Xian Gong Si 2201 Interest of corporation controlled by you
Tian Jin Shi Ji Yu Neng Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Bei Jing Shi Ji Yu Neng Ke Ji You Xian Gong Si 2501 Other

Mega Genomics Headlines

No Headlines